The diagnostic imaging industry has undergone significant strategic reconfiguration through M&A, driven by three converging forces: the race to acquire AI software capabilities, the build-out of cloud-based enterprise imaging platforms, and the explosive growth of radiopharmaceuticals and theranostics. GE HealthCare's planned $2.3 billion acquisition of Intelerad, Siemens Healthineers' series of AI imaging startup acquisitions, Bayer's $16.9 billion acquisition of Vividion, and Lantheus' strategic expansion into theranostics collectively illustrate the transformation underway. Chinese manufacturers led by Mindray and United Imaging are simultaneously acquiring international distribution and technology assets to accelerate global expansion beyond their home market.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• M&A Transaction Analysis — Strategic Rationale, Valuations, and Competitive Implications
• AI Software and Clinical Decision Support Acquisitions
• Cloud PACS and Enterprise Imaging Platform Acquisitions
• Radiopharmaceutical and Theranostics Acquisitions
• Emerging Market Scale Acquisitions
• Partnership and Joint Venture Activity 2023–2026
• Competitive Implications — Market Share Shifts and Strategic Positioning
• Outlook — Likely Targets and Deal Activity 2026–2028
Table of Contents
1. Executive Summary
2. Overview
3. Imaging Systems M&A
4. AI and Software M&A
5. Radiology IT M&A
6. Point-of-Care Imaging M&A
7. Financial Analysis
8. Strategic Rationale
9. Integration Outcomes
10. Outlook 2026-2028
11. Competitive Landscape
12. Strategic Conclusions
13. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Canon Medical
Fujifilm Healthcare
GE HealthCare
Hologic
Intelerad
Mindray
Philips
Siemens Healthineers